MétaCan
Menu
Back to cohort

Benefit–risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations

2021· review· en· W3199557265 on OpenAlexaff
Bethea A. Kleykamp, Robert H. Dworkin, Dennis C. Turk, Zubin Bhagwagar, Penney Cowan, Christopher Eccleston, Susan S. Ellenberg, Scott Evans, John T. Farrar, Roy Freeman, Louis P. Garrison, Jennifer S. Gewandter, Veeraindar Goli, Smriti Iyengar, Alejandro R. Jadad, Mark P. Jensen, Roderick Junor, Nathaniel P. Katz, J. Patrick Kesslak, Ernest A. Kopecky, Dmitri Lissin, John D. Markman, Michael P. McDermott, Philip J. Mease, Alec O'connor, Kushang V. Patel, Srinivasa N. Raja, Michael C. Rowbotham, Cristina Sampaio, Jasvinder A. Singh, Ilona Steigerwald, Vibeke Strand, Leslie Tive, Jeffrey Tobias, Ajay D. Wasan, Hilary Wilson

Bibliographic record

VenuePain · 2021
Typereview
Languageen
FieldEconomics, Econometrics and Finance
TopicHealth Systems, Economic Evaluations, Quality of Life
Canadian institutionsUniversity of Toronto
FundersNational Center for Advancing Translational SciencesNational Institute of Neurological Disorders and StrokeNational Heart, Lung, and Blood InstituteU.S. Food and Drug Administration
KeywordsMedicineChronic painRandomized controlled trialClinical trialPhysical therapyMEDLINERisk assessmentAlternative medicineSystematic reviewIntensive care medicineInternal medicinePathology

Abstract

fetched live from OpenAlex

ABSTRACT: Chronic pain clinical trials have historically assessed benefit and risk outcomes separately. However, a growing body of research suggests that a composite metric that accounts for benefit and risk in relation to each other can provide valuable insights into the effects of different treatments. Researchers and regulators have developed a variety of benefit-risk composite metrics, although the extent to which these methods apply to randomized clinical trials (RCTs) of chronic pain has not been evaluated in the published literature. This article was motivated by an Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials consensus meeting and is based on the expert opinion of those who attended. In addition, a review of the benefit-risk assessment tools used in published chronic pain RCTs or highlighted by key professional organizations (ie, Cochrane, European Medicines Agency, Outcome Measures in Rheumatology, and U.S. Food and Drug Administration) was completed. Overall, the review found that benefit-risk metrics are not commonly used in RCTs of chronic pain despite the availability of published methods. A primary recommendation is that composite metrics of benefit-risk should be combined at the level of the individual patient, when possible, in addition to the benefit-risk assessment at the treatment group level. Both levels of analysis (individual and group) can provide valuable insights into the relationship between benefits and risks associated with specific treatments across different patient subpopulations. The systematic assessment of benefit-risk in clinical trials has the potential to enhance the clinical meaningfulness of RCT results.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.629
metaresearch head score (Gemma)0.227
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesMetaresearch
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.974
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.6290.227
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0100.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.834
GPT teacher head0.659
Teacher spread0.175 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2021
Admission routes1
Has abstractyes

Explore more

Same venuePainSame topicHealth Systems, Economic Evaluations, Quality of LifeFrench-language works237,207